From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma
Top Cited Papers
Open Access
- 8 January 2025
- journal article
- editorial
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (2) , 327
Abstract
Multiple Myeloma (MM) is a complex hematological malignancy characterized by the clonal proliferation of malignant plasma cells within bone marrow (BM)Keywords
This publication has 46 references indexed in Scilit:
- Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialThe Lancet Haematology, 2019
- Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcomeAnnals of Hematology, 2019
- Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen SensitivityImmunity, 2018
- Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatmentBlood Cancer Journal, 2016
- High level of interleukin-10 in serum predicts poor prognosis in multiple myelomaBritish Journal of Cancer, 2016
- Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblastBone, 2015
- Angiogenesis and Multiple MyelomaCancer Microenvironment, 2011
- Bone marrow microenvironment and the identification of new targets for myeloma therapyLeukemia, 2008
- Interleukin-6 dependence of advanced malignant plasma cell dyscrasiasCancer, 1992